Skip to content

Randomized, cross-over, controlled study of Clomastine fumarate in the treatment of Williams syndrome

Randomized, cross-over, controlled study of Clomastine fumarate in the treatment of Williams syndrome

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500105345
Enrollment
Unknown
Registered
2025-07-02
Start date
2024-02-20
Completion date
Unknown
Last updated
2025-07-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Williams syndrome

Interventions

treatment group:Clemastine Fumarate
control group:Placebo

Sponsors

Qilu Hospital of Shandong University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
3 Years to 12 Years

Inclusion criteria

Inclusion criteria: 1.Age 3-12 years old; 2.GTF2I gene mutation was detected by whole exon; 3.Positive fluorescence in situ hybridization (FISH) test confirmed the diagnosis, showing chromosome 7q11.23 with 1.55 mb of microdeletion; 4.The subject and/or guardian sign the informed consent, agreeing to cooperate with the investigator throughout the clinical trial and collect clinical data and peripheral blood and urine samples;

Exclusion criteria

Exclusion criteria: 1.WS patients with other genetic mutations; 2.Antihistamines, monoamine oxidase inhibitors, barbiturates, and sedatives, as well as medications affecting cognitive behavior, limb movement, white matter myelin, and MRI in the 2 months prior to enrollment; 3.Fever (body temperature above 37.3 ° C); 4.Parents or children with infectious or neurodegenerative diseases are not eligible for experimental testing; 5.He has narrow-angle glaucoma, narrow peptic ulcer, pyloric duodenal obstruction, hyperthyroidism, symptomatic prostatic hypertrophy, and bladder neck obstruction. With severe immunodeficiency disease; 6.Allergic to Clomastine fumarate or other arylalkylamine antihistamines or any receptor; 7.Based on recent MRI and interpretation by neuroradiologists or WS, significant brain lesions were found that were not associated with WS disease; 8.Clinically significant metabolic, hematological, liver, immune, urinary, endocrine, neurological, pulmonary, psychiatric, skin, allergy, kidney, or other major conditions that may affect the interpretation of study findings or patient safety in WS's judgment; 9.Children deemed unsuitable for inclusion by other investigators;

Design outcomes

Primary

MeasureTime frame
Fractional Anisotropy;Social cognition score;Score of execution ability;

Secondary

MeasureTime frame
Score of Gesell Development Scale;Score of Wechsler Intelligence Scale for Children, fourth edition;Score of Vinland scale;Radial diffusivity;Clinical efficacy improvement score;

Countries

China

Contacts

Public ContactCao aihua

Qilu Hospital of Shandong University

xinercah@163.com+86 185 6008 6317

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026